Skip to main content

Table 1 Summary of results from studies reporting anti-HCV prevalence in the general population

From: Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

Author, year Country Recruiting period Population as reported Age, mean (SD) Sample size Anti-HCV prevalence (%) (95% CI) Risk of selection bias
Viejo, 2018 [19] Spain February–April 2017 The general adult population living in the health area of Callosa D’En Sarrià 47.5 (−) 2637 1.14 (0.73–1.55) High risk
Lavin, 2017 [20] Spain 2015–2016 Spanish adult population 6839 1.11 (−) Low risk
Quesada, 2015 [21] Spain 1994–2005 Women from the general population in different geographical areas worldwide 40.0(15.6) 314 0.60 (0.20–2.50) High risk
Andriulli, 2018 [22] Italy 2015 The general population 4907 2.30 (−) Low risk
Morisco, 2017 [23] Italy May 14 A random 1:3 systematic sample of the adult general population of Naples 49.9(5.00) 1315 3.00 (2.10–4.00) Low risk
Walewska-Zielecka, 2017 [24] Poland 2004–2014 Patients who had been tested for anti-HCV at least once in the period from 2004 to 2014 34.4(8.6) 61805 1.50 (−) High risk
Clifford, 2017 [25] Poland 2004–2009 The general female population 37.0(−) 909 0.80 (0.30–1.60) High risk
Garvey, 2017 [26] Ireland April–June 2014 and November 2015–February 2016 The adult population in Ireland with probability proportional to the general population age-sex distribution 3759 0.98 (−) Low risk
Chlibek, 2017 [27] Czech Republic February 2015–September 2015 The adult general population 47.1(17.1) 3000 1.67 (1.27–2.19) High risk
Carvalhana, 2016 [28] Portugal April 2012–December 2014 Adults from primary care settings in mainland Portugal 50.2(18.3) 1627 0.54 (0.20–0.90) Low risk
Plompen, 2015 [29] Netherland The general Dutch elderly population 69.5(9.0) 6036 0.56 (−) High risk